<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Johnson & Johnson Services, Inc.

    Johnson & Johnson Services, Inc.

    Johnson & Johnson engages in the research and development, manufacture, and sale o...

    Johnson & Johnson engages in the research and d...

    Filing Type:    PU
    Harrow Health, Inc.

    Harrow Health, Inc.

    Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, incl...

    Harrow Health, Inc. (NASDAQ: HROW) owns a portf...

    Filing Type:    PU
    Scottline Healthcare Solutions, Inc

    Scottline Healthcare Solutions, Inc

    Scottline helps healthcare organizations establish a secure, agile digital infrast...

    Scottline helps healthcare organizations establ...

    Filing Type:    RARD
    CHF Solutions, Inc.

    CHF Solutions, Inc.

    CHF Solutions is focused on improving the quality of life for patients suffering f...

    CHF Solutions is focused on improving the quali...

    Filing Type:    PU
    ENDRA Life Sciences Inc.

    ENDRA Life Sciences Inc.

    ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broade...

    ENDRA Life Sciences' mission is to bring new ca...

    Filing Type:    PU
    Harpoon Therapeutics, Inc.

    Harpoon Therapeutics, Inc.

    Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel ...

    Harpoon Therapeutics is a clinical-stage immuno...

    Filing Type:    PU
    Trillium Therapeutics Inc.

    Trillium Therapeutics Inc.

    Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing ...

    Trillium Therapeutics Inc. is a clinical stage ...

    Filing Type:    PU
    TCR2 Therapeutics Inc.

    TCR2 Therapeutics Inc.

    TCR² is an innovative immunotherapy company developing the next generation of T c...

    TCR² is an innovative immunotherapy company de...

    Filing Type:    PU
    Midatech Pharma PLC

    Midatech Pharma PLC

    Midatech is an international specialty pharmaceutical company focused on the devel...

    Midatech is an international specialty pharmace...

    Filing Type:    PU
    Forty Seven, Inc.

    Forty Seven, Inc.

    Forty Seven is a clinical-stage immuno-oncology company focused on developing nove...

    Forty Seven is a clinical-stage immuno-oncology...

    Filing Type:    PU
    Merus N.V.

    Merus N.V.

    Merus is a clinical-stage immuno-oncology company developing innovative full-lengt...

    Merus is a clinical-stage immuno-oncology compa...

    Filing Type:    PU
    Aethlon Medical, Inc.

    Aethlon Medical, Inc.

    At Aethlon Medical, we are a leading developer of immunotherapeutic technologies t...

    At Aethlon Medical, we are a leading developer ...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.